BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 15691639)

  • 21. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
    Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
    Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
    Rao S; Cunningham D; Hawkins RE; Hill ME; Smith D; Daniel F; Ross PJ; Oates J; Norman AR
    Br J Cancer; 2005 May; 92(9):1650-4. PubMed ID: 15856037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
    Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
    J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
    Lim JY; Jeung HC; Mun HS; Lee DK; Paik YH; Lee SJ; Yoon DS; Cho JY
    Anticancer Drugs; 2008 Jul; 19(6):631-5. PubMed ID: 18525323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
    Papadimitriou CA; Papakostas P; Karina M; Malettou L; Dimopoulos MA; Pentheroudakis G; Samantas E; Bamias A; Miliaras D; Basdanis G; Xiros N; Klouvas G; Bafaloukos D; Kafiri G; Papaspirou I; Pectasides D; Karanikiotis C; Economopoulos T; Efstratiou I; Korantzis I; Pisanidis N; Makatsoris T; Matsiakou F; Aravantinos G; Kalofonos HP; Fountzilas G
    BMC Med; 2011 Jan; 9():10. PubMed ID: 21281463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
    Riva C; Lavieille JP; Schmerber S; Cuisnie O; Reyt E
    Int J Oncol; 2000 Sep; 17(3):543-9. PubMed ID: 10938396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer.
    Shen YC; Li CP; Yen CJ; Hsu C; Lin YL; Lin ZZ; Chen LT; Su WC; Chao Y; Yeh KH; Cheng AL
    Oncology; 2014; 87(2):104-13. PubMed ID: 25011938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
    Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
    Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.
    Hospers GA; Schaapveld M; Nortier JW; Wils J; van Bochove A; de Jong RS; Creemers GJ; Erjavec Z; de Gooyer DJ; Slee PH; Gerrits CJ; Smit JM; Mulder NH
    Ann Oncol; 2006 Mar; 17(3):443-9. PubMed ID: 16500914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
    Dahan L; Bonnetain F; Ychou M; Mitry E; Gasmi M; Raoul JL; Cattan S; Phelip JM; Hammel P; Chauffert B; Michel P; Legoux JL; Rougier P; Bedenne L; Seitz JF;
    Gut; 2010 Nov; 59(11):1527-34. PubMed ID: 20947887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma.
    Seitz JF; Perrier H; Giovannini M; Capodano G; Bernardini D; Bardou VJ
    J Chemother; 1998 Jun; 10(3):258-65. PubMed ID: 9669654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
    Zori Comba A; Blajman C; Richardet E; Bella S; Vilanova M; Cóppola F; Van Kooten M; Rodger J; Giglio R; Balbiani L; Perazzo F; Montiel M; Chacón M; Pujol F; Mickiewicz E; Cazap E; Recondo G; Lastiri F; Simon J; Wasserman E; Schmilovich A
    Eur J Cancer; 2001 May; 37(8):1006-13. PubMed ID: 11334726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC).
    Di Costanzo F; Bartolucci R; Calabresi F; Sofra M; Marzola M; Belsanti V; Boni C; Bacchi M
    Ann Oncol; 1992 May; 3(5):371-6. PubMed ID: 1616890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
    Di Costanzo F; Gasperoni S; Malacarne P; Belsanti V; Luppi G; Marzola M; Corgna E; Sdrobolini A; Passalacqua R; Figoli F; Algeri R; Zironi S; Angiona S; Boni C
    Am J Clin Oncol; 1998 Aug; 21(4):369-75. PubMed ID: 9708636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
    Schrijvers D; Johnson J; Jiminez U; Gore M; Kosmidis P; Szpirglas H; Robbins K; Oliveira J; Lewensohn R; Schüller J; Riviere A; Arvay C; Langecker P; Jacob H; Cvitkovic E; Vokes E
    J Clin Oncol; 1998 Mar; 16(3):1054-9. PubMed ID: 9508190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.